Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
Information source: Medical Centre of Postgraduate Education, Poland
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hip Osteoarthritis; Blood Loss
Intervention: Enoxaparin (Drug); rivaroxaban (Drug); dabigatran (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Medical Centre of Postgraduate Education, Poland Official(s) and/or principal investigator(s): Marcin K Wasko, M.D., Ph.D., Principal Investigator, Affiliation: The Medical Centre of Postgraduate Education, Department of Orthopaedics and Inflammatory Disorders of Locomotor System
Overall contact: Marcin K Wasko, M.D., Ph.D., Phone: +48227794031, Ext: 384, Email: m.wasko@cmkp.edu.pl
Summary
The purpose of this study is to determine which of the following drugs: enoxaparin,
dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).
Clinical Details
Official title: Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care
Primary outcome: Total blood loss by the 3rd postoperative day
Secondary outcome: Drop in the haemoglobin value between 3rd day postop and preoperativeWound healing disturbances according to the definition of Centers for Disease Control and Prevention
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- primary, end-stage hip osteoarthritis requiring total hip arthroplasty
Exclusion Criteria:
- inflammatory arthropathies
- liver disorders
- neoplastic conditions
- clotting disorders
Locations and Contacts
Marcin K Wasko, M.D., Ph.D., Phone: +48227794031, Ext: 384, Email: m.wasko@cmkp.edu.pl
Prof. A. Gruca Teaching Hospital, The Medical Centre of Postgraduate Education, Otwock, Woj. Mazowieckie 05-400, Poland; Recruiting Marcin K Wasko, M.D., Ph.D., Principal Investigator
Additional Information
Starting date: July 2012
Last updated: March 13, 2014
|